Detailed Information

Cited 12 time in webofscience Cited 12 time in scopus
Metadata Downloads

Relationship Between Statin Type and Responsiveness to Clopidogrel in Patients Treated with Percutaneous Coronary Intervention: A Subgroup Analysis of the CILON-T Trial

Authors
Suh, Jung-WonCha, Myung-JinLee, Seung-PyoChae, In-HoBae, Jang-HoKwon, Taek-GeunBae, Jang-WhanCho, Myeong-ChanRha, Seung-WoonKim, Hyo-Soo
Issue Date
2014
Publisher
JAPAN ATHEROSCLEROSIS SOC
Keywords
Atorvastatin; Rosuvastatin; Clopidogrel; Platelet function
Citation
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, v.21, no.2, pp 140 - 150
Pages
11
Indexed
SCIE
SCOPUS
Journal Title
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS
Volume
21
Number
2
Start Page
140
End Page
150
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/10006
DOI
10.5551/jat.19265
ISSN
1340-3478
1880-3873
Abstract
Aim: To compare the responsiveness to clopidogrel in patients who were prescribed two different types of statins, atorvastatin vs. rosuvastatin, following percutaneous coronary intervention. Methods: A total of 915 patients were randomized according to the antiplatelet therapy strategy in the CILON-T trial. In this subgroup analysis, we included patients who took atorvastatin (20 mg/day, n=295) or rosuvastatin (10 mg/day, n=261) during the entire study period and underwent measurement of the P2Y12 reaction unit (PRU) values at both discharge and six months. We compared the P2Y12 reaction unit (PRU) values at six months and investigated the relationship between the genotypes of cytochrome P450 (CYP) 3A4, 3A5 and 2C19 with the PRU values at six months in both groups. Results: The baseline characteristics did not differ between the groups. There were no significant differences in the PRU values at discharge (atorvastatin 221.0 +/- 87.3 vs. rosuvastatin 217.1 +/- 84.7, p=0.59). However, the rosuvastatin group had higher PRU values than the atorvastatin group at six months (atorvastatin 226.4 +/- 79.3 vs. rosuvastatin 241.5 +/- 88.2, p=0.033). In the genotype analysis, the number of CYP2C19 loss-of-function (LOF) alleles (*2 or *3) was positively associated with a higher PRU value in both statin groups, and there were no significant interactions regarding the PRU values between the number of CYP 2C19 LOF alleles and the type of statin (p for interaction=0.56). In the multivariate analysis, the use of rosuvastatin was a significant predictor of a PRU value of >273 (the highest tertile) (OR 1.67, 95% confidence interval 1.05-2.65, p=0.031). Conclusions: Rosuvastatin is associated with high on-treatment platelet reactivity compared with atorvastatin following the coadministration of clopidogrel for six months. Further studies are therefore warranted to clarify the mechanism underlying this relationship.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Cardiology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Rha, Seung Woon photo

Rha, Seung Woon
Guro Hospital (Department of Cardiology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE